Purchase this article with an account.
Milan Shah, Cherry Wan, Barry Kapik, Thomas A Ciulla; Post hoc Analysis of Clinical Suprachoroidal Injection Experience for Non-infectious Uveitis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1192.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze procedural characteristics of suprachoroidal injections (SCIs) using the SCS Microinjector® in two uveitis trials.The SCS Microinjector reliably delivers drug to the suprachoroidal space (SCS), an alternative administration route for chorioretinal diseases. SCIs are first attempted with a 900µm length needle and switched to 1100µm length if required. Correlations between needle length, baseline patient characteristics, and physician device experience, via survey, are presented.
Post hoc analyses were performed to assess the relationship between needle length for baseline SCI and patient characteristics. Univariate analysis was conducted with Pearson chi-square analysis for categorial variables and the biserial correlation for continuous variables. Multivariate logistical regression was run to confirm univariate findings. Furthermore, a user experience survey was completed to evaluate real-world SCI experience.
Of the 133 total baseline SCIs,74% were completed with the 900µm needle; the remaining with the 1100µm needle. Univariate analysis revealed no relationship between needle length used and gender, lens status, uveitis sub-type, disease course or onset. Disease duration was statistically correlated with needle length:91% of injections were completed with the 900µm needle for Limited (≤3 months) and 70% for Persistent (>3 months). Age was moderately inversely correlated with needle length. SCI quadrant was statistically related: 82% of supratemporal injections were completed with the 900µm needle compared to 45% of injections administered superonasally. Multivariate logistical regression verified univariate analysis demonstrating the potential impact of age, disease duration and SCI quadrant on needle length. In the user experience survey, over 80% of the physicians responded that SCIs presented no new challenges compared to other types of injections.
While these analyses are retrospective with a small sample size, few patient characteristics were found to correlate with needle length, indicating the procedure can be completed for the majority of patients with the 900µm needle and using a 1100µm needle in remaining patients. This suggests that SCIs with the SCS Microinjector has potential to reliably and repeatably deliver drugs for chorioretinal diseases in an in-office setting.
This is a 2021 ARVO Annual Meeting abstract.
Needle Length Distributions by (a) Injection Quadrant and (b) Disease Duration
This PDF is available to Subscribers Only